Compare Pfizer Inc (PFE) vs Solaredge Technologies Inc (SEDG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Solaredge Technologies Inc — how do they compare? Pfizer Inc trades at $27.77 (market cap $158.56B), while Solaredge Technologies Inc trades at $32.8 (market cap $2.00B). The key difference: Pfizer Inc is far larger — about 79.3× Solaredge Technologies Inc's market cap, and Pfizer Inc pays a 6.18% dividend while Solaredge Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Solaredge Technologies Inc for 34 Days on average.
| PFE | SEDG | |
|---|---|---|
Market Cap | $158.56B | $2.00B |
Volume | 44,138,282 | 2,739,860 |
Sector | Health | Energy |
52-Week High | $29.02 | $78.51 |
52-Week Low | $23.67 | $28.47 |
Typical Hold Time | 158 Days | 34 Days |
Enterprise Value | $210.06B | $1.86B |
Dividend Yield | 6.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
SolarEdge Technologies (SEDG) trades at $33.16, down 2.59% with bearish technical signals and mixed fundamentals. The company shows revenue recovery to $1.18B in 2025 but continues posting significant losses with a -20.29% net margin. Recent news highlights legal investigations and AI data center initiatives, while analyst sentiment remains cautious with a $37.75 consensus target.
The outlook remains challenging with persistent profitability issues and legal overhangs, though the AI data center expansion offers long-term potential. Key risks include ongoing losses, high debt levels, and solar industry headwinds. The stock presents speculative appeal for investors betting on a turnaround, but requires careful risk assessment given the current financial strain.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Solaredge Technologies Inc
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →
